Public Health Vaccines to Develop Vaccines against Infectious Disease Threats, including Marburg virus and Sudan ebolavirus

    CAMBRIDGE, MA, February 07, 2019 /24-7PressRelease/ -- Public Health Vaccines, LLC (PHV), a biotechnology company out of Cambridge, MA, has entered into a license arrangement with the Public Health Agency of Canada (PHAC) to leverage the advanced recombinant vesicular stomatitis virus (rVSV) vector platform that PHAC discovered in 2005, to develop vaccines against Marburg virus and Sudan ebolavirus.

The rVSV Marburg virus and rVSV Sudan ebolavirus vaccines represent real solutions to significant and current public health threats. The platform technology has been shown effective in primate models both pre- and post-exposure for the targeted indications. In addition, the efficacy, safety (more than 50,000 people vaccinated), manufacturing, and regulatory approach have been demonstrated for a similar indication.

PHV Co-Founder and Board Member Dr. Thomas Monath explains, "We are enthusiastic about the opportunity to develop these much-needed vaccines and contribute to global public health. We are also grateful to PHAC for the trust they have put in the PHV team to shepherd these additional rVSV vaccine candidates through to licensure and launch."

"The development of these vaccines demonstrates how the Government of Canada's research and expertise is enabling innovation that can make a real difference in the lives of people around the world," said Dr. Theresa Tam, Chief Public Health Officer of Canada. "Vaccines are critical to addressing public health threats including viral hemorrhagic fevers like Marburg virus and Sudan ebolavirus."

PHV have compiled a team of seasoned industry veterans with years of vaccine development experience, including the exact functional expertise that successfully managed and executed the recent development of the rVSV Ebola vaccine using the same core platform technology under two United States federally-funded contracts. This relevant and specific experience should significantly accelerate and de-risk vaccine development efforts.

PHV's initial focus will be on the development of Marburg virus and Sudan ebolavirus vaccines. However, the company will eventually broaden its focus to include other vaccine development opportunities that align with the company's core public health objective.

About Public Health Vaccines, LLC.

Public Health Vaccines, LLC. (PHV), headquartered in Cambridge, Massachusetts, is a privately-held biotechnology company developing vaccines for the prevention and control of emerging infectious diseases. The company's initial focus is to develop vaccines against Marburg virus and Sudan ebolavirus (MARV and SUDV) utilizing the rVSV platform.

For more information, please visit www.phvaccines.com or email [email protected].

# # #